TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30663859

Group type: EXPERIMENTAL
Intervention: Brief Observation of Social Communication Change (BOSCC) during home snack routines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief Observation of Social Communication Change (BOSCC) during play routines
Number of subjects: 0
Study: 28027010

Group type: EXPERIMENTAL
Intervention: Exercise-for-mood intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard exercise-for-fitness intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 152
Study: 27215279

Group type: EXPERIMENTAL
Intervention: 10 μg recombinant HepB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 μg recombinant HepB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 μg recombinant HepB vaccine (adults)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 μg recombinant HepB vaccine (adults ages 15-24)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dosage of HepB vaccine (adults ages 25 and older)
Number of subjects: 0
Study: 23281382

Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine (LAM) 100 mg/d plus adefovir dipivoxyl (ADV) 10 mg/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Adefovir dipivoxyl (ADV) 10 mg/d
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination therapy of lamivudine (LAM) and adefovir dipivoxyl (ADV)
Number of subjects: 81
Study: 20179232

Group type: EXPERIMENTAL
Intervention: Hydrogen sulfate (Hyd-Sulfate) capsule of AZD6244 (75 mg twice daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hydrogen sulfate (Hyd-Sulfate) capsule
Number of subjects: 59
Study: 17268205

Group type: EXPERIMENTAL
Intervention: Biventricular therapy (biventricular therapy + defibrillator)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (implantable cardioverter-defibrillator alone)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biventricular therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 15592021

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic radical nephrectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic radical nephrectomy
Number of subjects: 102
Study: 12113615

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg kg(‐1) followed 2 min later by rocuronium 0.54 mg kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Priming dose of 0.10 mg kg(‐1) followed 2 min later by rocuronium 0.50 mg kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg kg(‐1) followed 3 min later by administration 0.54 mg kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Priming dose of 0.10 mg kg(‐1) followed 3 min later by injection of 0.50 mg kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo injection followed 3 min later by rocuronium 0.60 mg kg(‐1)
Number of subjects: 75
Study: 9585800

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (200 mg saquinavir and 300 mg ritonavir)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (200 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (400 mg saquinavir and 300 mg ritonavir)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (400 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (600 mg saquinavir and 200 mg ritonavir)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ritonavir plus saquinavir (600 mg saquinavir and 600 mg ritonavir)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saquinavir alone
Number of subjects: 6
Study: 8590489

Group type: EXPERIMENTAL
Intervention: Triple airway manoeuvre (TAM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard method)
Number of subjects: 100
Study: 2146885

Group type: EXPERIMENTAL
Intervention: Urodilatin 50 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urodilatin 100 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urodilatin (all doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Urodilatin 25 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: ANF-(99-126) 50 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 404621

Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion (0.1 units/kg/hour)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Subcutaneous insulin injection
Number of subjects: 14
Study: 31847976

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 29490371

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Transitional Work
Number of subjects: 541
Study: 26816011

Group type: EXPERIMENTAL
Intervention: More-intensive belatacept regimen
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Less-intensive belatacept regimen
Number of subjects: 666

Group type: COMPARATOR
Intervention: Cyclosporine regimen
Number of subjects: 666
Study: 24492859

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) for malaria using artemether-lumefantrine (AL) with a six dose regimen.
Number of subjects: 5233

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) for malaria.
Number of subjects: 5233

Group type: COMPARATOR
Intervention: Control group (no IST intervention).
Number of subjects: 5233
Study: 23027646

Group type: EXPERIMENTAL
Intervention: Cutting Edge Tests to assess diabetes complications
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Annual Evaluations
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Help Others
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Better Care for Diabetes
Number of subjects: 1334
Study: 20870985

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 1020
Study: 17589421

Group type: EXPERIMENTAL
Intervention: morphine + morphine (MM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: morphine + remifentanil (MR)
Number of subjects: 100
Study: 17286117

Group type: EXPERIMENTAL
Intervention: Uniform-grey backgrounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural-scene backgrounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractal noise backgrounds
Number of subjects: 0
Study: 12419714

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.9%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propofol 100‐150 microgram.kg(‐1).min(‐1)
Number of subjects: 48
Study: 10025899

Group type: EXPERIMENTAL
Intervention: Chemotherapy with alkylating agents
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and other non-alkylating agents
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study: 7740509

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin) administered subcutaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered subcutaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin) administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Ardeparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 1696921

Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 6
Study: 7042603

Group type: EXPERIMENTAL
Intervention: Rifampin 450 mg daily (Regimen A)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rifampin 1200 mg once a month (Regimen B)
Number of subjects: 35
Study: 31597662

Group type: EXPERIMENTAL
Intervention: ME-344 10 mg/kg intravenous on days 8, 15, and 21
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ME-344 (in subgroup with vascular normalization)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (in subgroup with vascular normalization)
Number of subjects: 42
Study: 31758639

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 5047

Group type: COMPARATOR
Intervention: Non-SLE individuals (control)
Number of subjects: 5047
Study: 28887117

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment (14∼16 J/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (0 J/cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment
Number of subjects: 0
Study: 25790936

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 25
Study: 23710347

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 139
Study: 21159325

Group type: EXPERIMENTAL
Intervention: Observed in-session resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported motivation measures (Change Questionnaire & Client Motivational for Therapy Scale)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational interviewing prior to CBT
Number of subjects: 0
Study: 19076544

Group type: EXPERIMENTAL
Intervention: Lupine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pea
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Soy
Number of subjects: 39
Study: 17317428

Group type: EXPERIMENTAL
Intervention: Geriatric home hospitalization service (GHHS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: General medical ward (GMW)
Number of subjects: 73
Study: 15521851

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Tegaserod (both dosages)
Number of subjects: 2612
Study: 10561948

Group type: COMPARATOR
Intervention: Prenolol 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prenolol 100 mg
Number of subjects: 12
Study: 8919037

Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in keratinizing squamous cells in keratotic type seborrhoeic keratosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in keratinocytes at the periphery of the horn pearl in well-differentiated squamous cell carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression at the border between involved and noninvolved skin in psoriasis vulgaris
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annexin I mRNA expression in dyskeratotic epidermal keratinocytes in keratosis follicularis Darier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annexin I mRNA expression in basal and suprabasal cells of normal epidermis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annexin I mRNA expression in tumour cells in basal cell carcinoma
Number of subjects: 0
Study: 1747577

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus slow release nifedipine 20 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 6621623

Group type: COMPARATOR
Intervention: Fixed dose of 3500 IU of heparin subcutaneously every eight hours (Group 1)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Adjusted dose of heparin to maintain activated partial thromboplastin time between 31.5 and 36 seconds (Group 2)
Number of subjects: 79
Study: 31443692

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) at 200 mmHg, twice daily for 6 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group at 60 mmHg, twice daily for 6 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RIC group
Number of subjects: 37
Study: 28592257

Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment applied twice a day for 8 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment
Number of subjects: 8
Study: 25683077

Group type: EXPERIMENTAL
Intervention: 2 ml of 25% dextrose orally just before laser therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical anesthesia with paracaine eye drops
Number of subjects: 24
Study: 22230181

Group type: EXPERIMENTAL
Intervention: Professional development program for early childhood educators led by a speech-language pathologist, including 18 hours of group training and 3 individual coaching sessions.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Professional development program for early childhood educators led by a speech-language pathologist.
Number of subjects: 20
Study: 20413380

Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino technique (n=35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Dolphin technique (n=35)
Number of subjects: 70
Study: 18639659

Group type: EXPERIMENTAL
Intervention: Fibrin glue spray and collagen patch applied to the axillary fossa
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 50
Study: 15673354

Group type: EXPERIMENTAL
Intervention: Intervention social workers received baseline education in advance care planning, structured discussions, formal reviews, flagging of advance directives, and feedback on care congruence.
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control social workers received an educational training session on New York State law regarding advance directives but no additional training or interventions.
Number of subjects: 139
Study: 11791023

Group type: EXPERIMENTAL
Intervention: Drug-treated hypertension
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Drug-treated hypertension with target blood pressure below 130/85
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Inadequately treated hypertensives
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Untreated subjects with blood pressure 140/90 or above
Number of subjects: 6000
Study: 10347347

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 401

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 401
Study: 8610239

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on day 1 (Group A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 8 (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 15 and 12.5 mg/m2 on day 8 (Group C)
Number of subjects: 86
Study: 1934538

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin 5 mg twice daily
Number of subjects: 0
Study: 6304907

Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg per day for 20 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Natural estrogens (1.25 mg for 20 days)
Number of subjects: 43
Study: 30760299

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH) treatment comprising eight sessions followed by three booster sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo-inspired waitlist control group receiving weekly messages with positive expectations
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pure waitlist control group receiving weekly messages asking to fill in a questionnaire
Number of subjects: 60
Study: 29609573

Group type: EXPERIMENTAL
Intervention: Public awareness of H7N9
Number of subjects: 2969

Group type: EXPERIMENTAL
Intervention: Public awareness of MERS
Number of subjects: 2969

Group type: EXPERIMENTAL
Intervention: Knowledge score for H7N9
Number of subjects: 2969

Group type: EXPERIMENTAL
Intervention: Knowledge score for MERS
Number of subjects: 2969

Group type: EXPERIMENTAL
Intervention: Sources of outbreak information
Number of subjects: 2969
Study: 27487357

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, home-based medication management intervention delivered within 7 days after hospital discharge
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, home-based medication management intervention
Number of subjects: 155
Study: 24836205

Group type: EXPERIMENTAL
Intervention: Ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ataluren (in subgroup not using chronic inhaled tobramycin)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo (in subgroup not using chronic inhaled tobramycin)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 238
Study: 22854665

Group type: EXPERIMENTAL
Intervention: TLR9 agonist (CPG 7909) with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Number of subjects: 40
Study: 20795842

Group type: EXPERIMENTAL
Intervention: Atenolol therapy (100 mg/day for 5 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol therapy
Number of subjects: 15
Study: 17040921

Group type: EXPERIMENTAL
Intervention: GABA(A) receptor immunohistochemistry analysis in Huntington's disease cases
Number of subjects: 35

Group type: COMPARATOR
Intervention: GABA(A) receptor immunohistochemistry analysis in control cases
Number of subjects: 35
Study: 17560868

Group type: EXPERIMENTAL
Intervention: E2 1 mg plus drospirenone 2 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15090932

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (100 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (400 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (all doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sinemet 25/100 (control)
Number of subjects: 18
Study: 10929336

Group type: EXPERIMENTAL
Intervention: Halm-Zielke Instrumentation (HZI)
Number of subjects: 29
Study: 9237780

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 40
Study: 1558774

Group type: EXPERIMENTAL
Intervention: Continuous cotrimoxazole administration
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intermittent cotrimoxazole administration (3 days a week)
Number of subjects: 77
Study: 2951060

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31767581

Group type: EXPERIMENTAL
Intervention: SHIFT intervention (6-month program including a 6-hour education session, worksite champion support, and equipment provision such as a Fitbit and resistance bands/balls)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual-care control arm
Number of subjects: 168
Study: 29602225

Group type: EXPERIMENTAL
Intervention: Oral microbiota in children developing allergic disease (asthma)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral microbiota in healthy children
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gemella haemolysans in children developing allergies
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri and L. crispatus in healthy children
Number of subjects: 80
Study: 26831541

Group type: EXPERIMENTAL
Intervention: N-Acetyl-cysteine (NAC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24986943

Group type: EXPERIMENTAL
Intervention: 2 cm incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 cm incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 cm incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 22942167

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 151
Study: 19896336

Group type: EXPERIMENTAL
Intervention: Early behavioural intervention (EBI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 61
Study: 18694141

Group type: EXPERIMENTAL
Intervention: Automated outcomes surveillance system (DELTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical Process Control (SPC) and Bayesian Updating Statistics (BUS) methodologies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16298069

Group type: EXPERIMENTAL
Intervention: Probable medication overuse headache (pMOH)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Patients with pMOH
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Patients without pMOH
Number of subjects: 1861
Study: 11964279

Group type: EXPERIMENTAL
Intervention: 50 mg alternate-day oral prednisone
Number of subjects: 125

Group type: COMPARATOR
Intervention: 10 mg alternate-day oral prednisone
Number of subjects: 125
Study: 9856375

Group type: EXPERIMENTAL
Intervention: Nifedipine retard (NPA) 10 or 20 mg twice a day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (NGITS) 30 or 60 mg once a day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 or 10 mg once a day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 63
Study: 7654468

Group type: EXPERIMENTAL
Intervention: Estrogen and 1000 mg of supplemental calcium each day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen alone
Number of subjects: 0
Study: 2762589

Group type: EXPERIMENTAL
Intervention: Betamethasone (1 x 8 mg) and dixyrazine (4 x 10 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-dose metoclopramide (4 x 1 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine and high-dose metoclopramide
Number of subjects: 100